Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial

• Published in: Trials 2014-04, Vol.15 (1), p.107-107, Article 107
• Main Authors: Eskandary, Farsad, Bond, Gregor, Schwaiger, Elisabeth, Kikic, Zeljko, Winzer, Christine, Wahrmann, Markus, Marinova, Lena, Haslacher, Helmuth, Regele, Heinz, Oberbauer, Rainer, Böhmig, Georg A
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Analysis; Austria; Biomarkers - blood; Biopsy; Boronic Acids - administration & dosage; Bortezomib; Clinical Protocols; Clinics; Double-Blind Method; Glomerular Filtration Rate - drug effects; Graft Rejection - diagnosis; Graft Rejection - drug therapy; Graft Rejection - immunology; Graft Rejection - mortality; Graft Survival - drug effects; Humans; Immunity, Humoral - drug effects; Immunosuppressive Agents - administration & dosage; Isoantibodies - blood; Kidney - drug effects; Kidney - immunology; Kidney - pathology; Kidney - physiopathology; Kidney Transplantation - adverse effects; Kidney Transplantation - mortality; Proteasome Inhibitors - administration & dosage; Pyrazines - administration & dosage; Research Design; Sample Size; Study Protocol; Time Factors; Treatment Outcome
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/1745-6215-15-107

Despite major advances in transplant medicine, improvements in long-term kidney allograft survival have not been commensurate with those observed shortly after transplantation. The formation of donor-specific antibodies (DSA) and ongoing antibody-mediated rejection (AMR) processes may critically contribute to late graft loss. However, appropriate treatment for late AMR has not yet been defined. There is accumulating evidence that the proteasome inhibitor bortezomib may substantially affect the function and integrity of alloantibody-secreting plasma cells. The impact of this agent on the course of late AMR has not so far been systematically investigated. The BORTEJECT Study is a randomized controlled trial designed to clarify the impact of intravenous bortezomib on the course of late AMR. In this single-center study (nephrological outpatient service, Medical University Vienna) we plan an initial cross-sectional DSA screening of 1,000 kidney transplant recipients (functioning graft at ≥180 days; estimated glomerular filtration rate (eGFR) >20 ml/minute/1.73 m2). DSA-positive recipients will be subjected to kidney allograft biopsy to detect morphological features consistent with AMR. Forty-four patients with biopsy-proven AMR will then be included in a double-blind placebo-controlled intervention trial (1:1 randomization stratified for eGFR and the presence of T-cell-mediated rejection). Patients in the active group will receive two cycles of bortezomib (4 × 1.3 mg/m2 over 2 weeks; 3-month interval between cycles). The primary end point will be the course of eGFR over 24 months (intention-to-treat analysis). The sample size was calculated according to the assumption of a 5 ml/minute/1.73 m2 difference in eGFR slope (per year) between the two groups (alpha: 0.05; power: 0.8). Secondary endpoints will be DSA levels, protein excretion, measured glomerular filtration rate, transplant and patient survival, and the development of acute and chronic morphological lesions in 24-month protocol biopsies. The impact of anti-humoral treatment on the course of late AMR has not yet been systematically investigated. Based on the hypothesis that proteasome inhibition improves the outcome of DSA-positive late AMR, we suggest that our trial has the potential to provide solid evidence towards the treatment of this type of rejection. Clinicaltrials.gov: NCT01873157.